The Board of Directors of Allakos Inc. appointed Leo Redmond as Chief Financial Officer of the Company, effective upon commencement of his employment with the Company on or about August 1, 2019, to succeed Adam Tomasi, Ph.D. who will be remaining with the Company and continuing in his capacity as Chief Operating Officer. In such capacity, Mr. Redmond will assume the role of principal financial officer and principal accounting officer of the Company, replacing Dr. Tomasi in such role. Additionally, Dr. Tomasi will be acquiring the role of President of the Company from Robert Alexander, Ph.D., who will continue to serve as the Company's Chief Executive Officer.

Prior to joining the Company, Mr. Redmond served as Chief Financial Officer and Secretary at Presidio Pharmaceuticals, a clinical-stage pharmaceutical company, and from March 2013 to July 2019, he served as President, CFO and Secretary of Presidio Pharmaceuticals. Mr. Redmond has also served as a member of the board of directors of Presidio Pharmaceuticals since 2011. From December 2000 to December 2007, Mr. Redmond was Senior Director of Finance at Genentech Inc., a biotechnology company, which was acquired by Roche in March 2009.

From July 2004 to December 2007, Mr. Redmond also served as the CFO and Secretary for the Genentech Foundation for Biomedical Sciences. Prior to joining Genentech, Mr. Redmond worked for the GTE Corporation in various financial roles.